---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-24-000039"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:40:17.142395+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q2 net product rev $410M +34% YoY; HELIOS-B positive; guidance raised

## Summary
- Global net product revenue $410M, up 34% YoY; TTR business (ONPATTRO+AMVUTTRA) grew 37% YoY.
- HELIOS-B Phase 3 vutrisiran met primary endpoint (28% reduction composite); all-cause mortality reduced 36% in overall population.
- GAAP net loss $16.9M; non-GAAP net income $73.8M ($0.58 non-GAAP diluted EPS).
- Raised 2024 combined net product revenue guidance from $1.4-1.5B to $1.575-1.65B.
- Planned sNDA submission for vutrisiran using Priority Review Voucher; Phase 3 for ALN-TTRsc04 at year-end.

## SEC filing metadata
- accession: 0001178670-24-000039
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000039/0001178670-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867024000039/alny-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-24-000039
- JSON: https://secwatch.observer/filing/0001178670-24-000039.json
- Plain text: https://secwatch.observer/filing/0001178670-24-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.